CombinoNews
Mercado internacional > Productos
Productos para el mercado internacional
| Molecule | Dosage | Reference product |
|---|---|---|
| Acyclovir Lyophilised powder for solution for infusion |
250 mg | Zovirax® (Glaxo SmithKline) |
| Amoxycillin + clavulanic acid Powder for solution for injection |
500 mg/50 mg, 1 g/200 mg, 2 g/200 mg | Augmentin® (Glaxo SmithKline) |
| Cefepime Powder for solution for injection |
1 g, 2 g | Maxipime® (Bristol Myers Squibb)) |
| Cefonicid Powder and solvent for solution for injection |
500 mg, 1 g | Monocid® (Glaxo SmithKline) |
| Cefotaxime Powder and solvent for solution for injection Powder and solvent for solution for injection/infusion |
100 mg, 250 mg, 500 mg, 1 g 2 g |
Claforan® (Aventis Pharma) |
| Ceftazidime Powder and solvent for solution for injection Powder for solution for infusion |
500 mg, 1 g 1 g, 2 g |
Fortum® (Glaxo SmithKline) |
| Ceftriaxone Powder and solvent for injection Powder for infusion |
250 mg, 500 mg, 1 g 2 g |
Rocephin® (Roche) |
| Cis-atracurium Solution for injection |
2 mg/mL (5 mL and 10 mL), 5 mg/mL (30 mL) | Nimbex® (Glaxo SmithKline) |
| Cefuroxime (Sodium) Powder and solvent for solution for injection Powder for solution for injection/infusion |
250 mg, 750 mg 1500 mg |
Zinacef® (Glaxo SmithKline) |
| Clindamycin Solution for injection |
150 mg/ml (300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml) | Dalacin® (Pharmacia&Upjohn) |
| Dexketoprofen Solution for injection Concentrate for solution for infusion |
50 mg/2 mL | Enantyum® (Menarini) |
| Fluconazole Solution for infusion |
2 mg/ml (50 ml, 100 ml) | Diflucan® (Pfizer) |
| Flumazenil Solution for injection |
0,1 mg/ ml (5 ml, 10ml) | Anexate® (Roche) |
| Granisetron Concentrate for solution for injection |
3 mg/3 ml |
Kytril® (Roche) |
| Iron sucrose Solution for injection/concentrate solution for infusion |
20 mg/ml | Venofer® (Vifor) |
| Ketorolac Trometamol Solution for injection |
30 mg/ml |
Toradol® (Roche) |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability
may be restricted to certain markets or countries. April 2010
| Molecule | Dosage | Reference product |
|---|---|---|
| Levofloxacin Solution for infusion |
5 mg/ml (500 mg/100 ml) | Tavanic® (Aventis) |
| Meropenem Powder for solution for injection |
500 mg, 1g | Meronem® (AstraZeneca) |
| Midazolam Solution for injection |
1 mg/ml (5 mg/5 ml), 5 mg/ml (15 mg/3 ml and 50 mg/10 ml) | Hypnovel® (Roche) |
| Pamidronate Lyophilised powder for solution for infusion |
15 mg, 30 mg, 60 mg, 90 mg | Aredia® (Novartis) |
| Pantoprazole Lyophilised powder for solution for injection/infusion |
40 mg | Pantocarm®, Pantoloc® (Altana Pharma) |
| Paracetamol Solution for infusion |
10 mg/ml | Perfalgan®, Pantoloc® (Bristol Myers Squibb) |
| Phenytoin Solution for injection |
100 mg/2 ml 250 mg/5 ml |
Phenytoin® (Pfizer/ Rubió) |
| Piperacillin/Tazobactam Lyophilised powder and solvent for solution for injection Lyophilised powder for solution for injection |
2 g/0,25 g, 4 g/0,5 g |
Tazobac® (Wyeth) |
| Remifentanil Lyophilised powder for solution for injection/infusion |
1 mg, 2 mg, 5 mg | Ultiva® (Glaxo SmithKline) |
| Somatostatin Lyophilised powder and solvent for solution for infusion |
0,25 mg, 3 mg | Stilamin® (Serono, IT, NL, CH.) Aminopanc® (UCB, DE.) Modustatine® (Clin Midy, FR.) |
| Teicoplanina Lyophilised powder and solvent for solution for injection |
200 mg, 400 mg | Targocid® (Aventis Pharma) |
| Vancomycin Lyophilised powder for solution for injection |
500 mg, 1 g | Vancocin® (Lilly) |
| Zidovudine Capsule Oral solution Tablets |
100 mg, 250 mg, 300 mg 50 mg/5 ml 300 mg |
Retrovir® (Glaxo SmithKline) |
| Zoledronic Concentrate for solution for infusion |
4 mg/5 mL |
Zometa® (Novartis) |
Note:Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability
may be restricted to certain markets or countries. April 2010
| Molecule | Dosage | Reference product |
|---|---|---|
| Acyclovir Cream Tablets |
5 % 800 mg |
Zovirax® (Glaxo SmithKline) |
| Dexketoprofen Solution for injection Concentrate for solution for infusion |
50 mg, 2 mL | Enantyum® (Menarini) |
| Doxazosin Tablets |
2 mg, 4 mg | Cardura® (Pfizer) |
| Fluoxetine Capsules |
20 mg |
Prozac® (Lilly) |
| Gabapentin Tablets Capsules |
600 mg, 800 mg 100 mg, 300 mg, 400 mg |
Neurontin® (Pfizer) |
| Glimepiride Tablets |
1 mg, 2 mg, 3 mg, 4 mg, 6 mg | Amaryl® (Aventis Pharma) |
| Glucosamine Sulphate Powder for oral solution |
1500 mg | Xicil® (Rottapharm) |
| Ibuprofen-lysine Powder for oral solution |
400 mg, 600 mg | Algidrin® (Fardi) |
| Memantine Film-Coated Tablets |
10 mg | Axura® (Merz Pharmaceutical) |
| Mirtazapine Film-Coated Tablets |
15 mg, 30 mg, 45 mg | Rexer® (Organon) |
| Pantoprazole Gastro-resistant tablets |
20 mg, 40 mg | Pantozol® (Altana Pharma) |
| Quetiapine Film-coated tablets |
25 mg, 100 mg, 200 mg, 300 mg | Seroquetel® (AstraZeneca) |
| Venlafaxine IR Tablets |
37,5 mg, 50 mg, 75 mg | Effexor® (Wyeth) |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability
may be restricted to certain markets or countries. April 2010